Full Text Journal Articles by
Author Maximilian von Eynatten

Advertisement

Find full text journal articles






Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund,

BACKGROUND:Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS:The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):949-959]

Cited: 0 times

View full text PDF listing >>



Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

Bettina J Kraus, Matthew R Weir, George L Bakris, Michaela Mattheus, David Z I Cherney, Naveed Sattar, Hiddo J L Heerspink, Ivana Ritter, Maximilian von Eynatten, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, Audrey Koitka-Weber,

Treatment with sodium-glucose co-transporter-2 inhibitors induces an initial 3-5 ml/min/1.73 m2 decline in estimated glomerular filtration rate (eGFR). Although considered to be of hemodynamic origin and largely reversible, this 'eGFR dip' may cause concern in clinical practice, which highlights the need to better understand its incidence and clinical implications. In ... Read more >>

Kidney Int (Kidney international)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.

Adeera Levin, Vlado Perkovic, David C Wheeler, Stefan Hantel, Jyothis T George, Maximilian von Eynatten, Audrey Koitka-Weber, Christoph Wanner, ,

BACKGROUND AND OBJECTIVES:In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), empagliflozin, in addition to standard of care, significantly reduced risk of cardiovascular death by 38%, hospitalization for heart failure by 35%, and incident or worsening nephropathy by 39% compared with placebo in patients ... Read more >>

Clin J Am Soc Nephrol (Clinical journal of the American Society of Nephrology : CJASN)
[2020, 15(10):1433-1444]

Cited: 0 times

View full text PDF listing >>



Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.

Christoph Wanner, Silvio E Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T George, Maximilian von Eynatten, Sibylle J Hauske, ,

AIM:To explore the cardiovascular (CV) and kidney effects of empagliflozin in patients with different clinical phenotypes of diabetic kidney disease (DKD) (i.e. with the presence or absence of overt albuminuria) participating in the EMPA-REG OUTCOME trial. MATERIALS AND METHODS:EMPA-REG OUTCOME randomized participants (1:1:1) to empagliflozin 10 mg, 25 mg or placebo, ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia.

Philipp M Lepper, Robert Bals, Peter Jüni, Maximilian von Eynatten,

Diabetologia (Diabetologia)
[2020, 63(11):2488-2490]

Cited: 1 time

View full text PDF listing >>



The authors reply.

Gert J Mayer, Christoph Wanner, Matthew R Weir, Silvio E Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z I Cherney,

Kidney Int (Kidney international)
[2020, 97(1):213-214]

Cited: 0 times

View full text PDF listing >>



Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.

Nobuya Inagaki, Wenying Yang, Hirotaka Watada, Linong Ji, Sven Schnaidt, Egon Pfarr, Tomoo Okamura, Odd Erik Johansen, Jyothis T George, Maximilian von Eynatten, Julio Rosenstock, Vlado Perkovic, Christoph Wanner, Mark E Cooper, John H Alexander, Issei Komuro, Masaomi Nangaku,

Objective:Linagliptin, a dipeptidyl peptidase-4 inhibitor, demonstrated cardiovascular and renal safety in type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) with albuminuria and/or kidney disease in the multinational CARMELINA® trial. We investigated the effects of linagliptin in Asian patients in CARMELINA®. Methods:T2DM patients with HbA1c 6.5-10.0% and established ... Read more >>

Diabetol Int (Diabetology international)
[2020, 11(2):129-141]

Cited: 1 time

View full text PDF listing >>



Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

Julio Rosenstock, Steven E Kahn, Odd Erik Johansen, Bernard Zinman, Mark A Espeland, Hans J Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Darren K McGuire, Nikolaus Marx, ,

Importance:Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator. Objective:This trial assessed cardiovascular outcomes of linagliptin vs glimepiride (sulfonylurea) in patients with relatively early type 2 diabetes and ... Read more >>

JAMA (JAMA)
[2019, :]

Cited: 25 times

View full text PDF listing >>



Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.

Vlado Perkovic, Audrey Koitka-Weber, Mark E Cooper, Guntram Schernthaner, Egon Pfarr, Hans J Woerle, Maximilian von Eynatten, Christoph Wanner,

BACKGROUND:Doubling of serum creatinine [equivalent to 57% reduction in estimated glomerular filtration rate (eGFR)] is an established surrogate for end-stage kidney disease (ESKD); however, this endpoint necessitates lengthy follow-up and large sample sizes in clinical trials. We explored whether alternative eGFR decline thresholds provide more feasible surrogate kidney endpoints. METHODS:The ... Read more >>

Nephrol Dial Transplant (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association)
[2019, :]

Cited: 2 times

View full text PDF listing >>



Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.

Gilbert Ledesma, Guillermo E Umpierrez, John E Morley, Diane Lewis-D'Agostino, Annett Keller, Thomas Meinicke, Sandra van der Walt, Maximilian von Eynatten,

AIM:To assess the addition of linagliptin as an alternative to insulin uptitration in older people with type 2 diabetes on stable insulin therapy. MATERIALS AND METHODS:This phase 4, randomized, multicentre, double-blinded, placebo-controlled, 24-week study recruited individuals on stable insulin, with baseline HbA1c 7.0%-10.0%, aged ≥60 years and body mass index ≤45 kg/m2 ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2019, 21(11):2465-2473]

Cited: 1 time

View full text PDF listing >>



Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Javed Butler, Faiez Zannad, David Fitchett, Bernard Zinman, Audrey Koitka-Weber, Maximilian von Eynatten, Isabella Zwiener, Jyothis George, Martina Brueckmann, Alfred K Cheung, Christoph Wanner,

Background In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes mellitus and established cardiovascular disease. Post hoc, we evaluated empagliflozin on kidney outcomes in patients with or without heart ... Read more >>

Circ Heart Fail (Circulation. Heart failure)
[2019, 12(6):e005875]

Cited: 0 times

View full text PDF listing >>



Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Mark E Cooper, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka-Weber,

Am. J. Kidney Dis. (American journal of kidney diseases : the official journal of the National Kidney Foundation)
[2019, 74(5):713-715]

Cited: 5 times

View full text PDF listing >>



Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Mark E Cooper, Vlado Perkovic, Per-Henrik Groop, Berthold Hocher, Uwe Hehnke, Thomas Meinicke, Audrey Koitka-Weber, Sandra van der Walt, Maximilian von Eynatten,

OBJECTIVE:Concomitant treatment with angiotensin-converting enzyme (ACE) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors is increasingly common. Pharmacological studies have suggested a potential adverse drug interaction between ACE inhibitors and DPP-4 inhibitors resulting in unfavorable hemodynamic changes; very few studies have examined such an interaction between angiotensin II receptor blockers (ARBs) and ... Read more >>

J Hypertens (Journal of hypertension)
[2019, 37(6):1294-1300]

Cited: 2 times

View full text PDF listing >>



Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

Gert J Mayer, Christoph Wanner, Matthew R Weir, Silvio E Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z I Cherney,

In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease, empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as hypertension and albuminuria, patients often receive other agents that alter intrarenal hemodynamics, including angiotensin converting enzyme ... Read more >>

Kidney Int (Kidney international)
[2019, 96(2):489-504]

Cited: 12 times

View full text PDF listing >>



Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.

Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka-Weber,

AIMS/INTRODUCTION:In the EMPA-REG OUTCOME® trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes and established cardiovascular disease. This exploratory analysis investigated the effects of empagliflozin on the kidneys in Asian patients. ... Read more >>

J Diabetes Investig (Journal of diabetes investigation)
[2019, 10(3):760-770]

Cited: 7 times

View full text PDF listing >>



Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent, Christoph Wanner,

[This corrects the article DOI: 10.1093/ckj/sfy090.]. ... Read more >>

Clin Kidney J (Clinical kidney journal)
[2020, 13(4):722]

Cited: 0 times

View full text PDF listing >>



Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.

Justyna Siwy, Thomas Klein, Marcel Rosler, Maximilian von Eynatten,

PURPOSE:Chronic kidney disease (CKD) is a serious complication of hyperglycemia and treatment options to slow its progression are scarce. Dipeptidyl peptidase-4 (DPP-4) inhibitors are common glucose-lowering drugs in type 2 diabetes (T2D). Among these, linagliptin has been suggested to exert kidney protective effects. It is investigated whether an effect of ... Read more >>

Proteomics Clin Appl (Proteomics. Clinical applications)
[2019, 13(2):e1800144]

Cited: 3 times

View full text PDF listing >>



Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

Darren K McGuire, John H Alexander, Odd Erik Johansen, Vlado Perkovic, Julio Rosenstock, Mark E Cooper, Christoph Wanner, Steven E Kahn, Robert D Toto, Bernard Zinman, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Nikolaus Marx, ,

BACKGROUND:Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes with the dipeptidyl ... Read more >>

Circulation (Circulation)
[2019, 139(3):351-361]

Cited: 23 times

View full text PDF listing >>



Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner, Bernard Zinman, Hans Juergen Woerle, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Darren K McGuire, ,

Importance:Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Objective:To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV ... Read more >>

JAMA (JAMA)
[2019, 321(1):69-79]

Cited: 106 times

View full text PDF listing >>



Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Hiddo J L Heerspink, Tom Greene, Hocine Tighiouart, Ron T Gansevoort, Josef Coresh, Andrew L Simon, Tak Mao Chan, Fan Fan Hou, Julia B Lewis, Francesco Locatelli, Manuel Praga, Francesco Paolo Schena, Andrew S Levey, Lesley A Inker, ,

BACKGROUND:Change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is lacking. We aimed to determine the association between treatment effects on early changes in albuminuria and treatment effects on clinical endpoints and surrograte endpoints, to ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2019, 7(2):128-139]

Cited: 20 times

View full text PDF listing >>



Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Christoph Wanner, Hiddo J L Heerspink, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Stefan Hantel, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten, Per-Henrik Groop, ,

BACKGROUND:Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. METHODS:Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, ... Read more >>

J Am Soc Nephrol (Journal of the American Society of Nephrology : JASN)
[2018, 29(11):2755-2769]

Cited: 14 times

View full text PDF listing >>



The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent, Christoph Wanner,

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin-angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure ... Read more >>

(Clinical kidney journal)
[2018, 11(6):749-761]

Cited: 26 times

View full text PDF listing >>



Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".

Christoph Wanner, Maximilian von Eynatten, Bernard Zinman,

Circulation (Circulation)
[2018, 138(8):850-851]

Cited: 0 times

View full text PDF listing >>



Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.

Petter Bjornstad, Lori Laffel, William V Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z I Cherney,

Diabetes Care (Diabetes care)
[2018, 41(8):e129-e130]

Cited: 4 times

View full text PDF listing >>



Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Julio Rosenstock, Vlado Perkovic, John H Alexander, Mark E Cooper, Nikolaus Marx, Michael J Pencina, Robert D Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C Broedl, Hans-Juergen Woerle, Jyothis T George, Maximilian von Eynatten, Darren K McGuire, ,

BACKGROUND:Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding their kidney efficacy and safety. The CARMELINA® trial aims to evaluate the effects of linagliptin, a DPP-4 inhibitor, on both CV and kidney outcomes in a study population enriched ... Read more >>

Cardiovasc Diabetol (Cardiovascular diabetology)
[2018, 17(1):39]

Cited: 30 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0942 s